News & Events

June 10, 2026

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment,...

May 18, 2026

BrainsWay Announces Minority-Stake Investment in Hopemark Health

Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay...

May 13, 2026

BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights

Revenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over...

May 9 - May 10, 2026

LONDON, UK

LONGEVITY MED SUMMIT 2026

BrainsWay will be participating in the Longevity Med Summit 2026, taking place on May 9–10 in London,...

, November 21, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Deep TMS™ becomes first and only TMS device cleared in treatment of patients ages 15 to 86 suffering...

June 12 - June 14, 2025

Clinical TMS Society (CTMSS)

BrainsWay is attending the CTMSS conference June 13th through June 14th, in San Diego, CA. We invite...

In the Media

November 24, 2025

FDA grants 510(k) clearance for TMS as adjunctive for major depressive disorder in young people

Key takeaways: BrainsWay Deep TMS is cleared for use by adolescents and adults with major depressive...

October 1, 2025

Serenity Mental Health Centers Adopting SWIFT Deep TMS

Serenity Mental Health Centers, one of the leading providers of Deep TMS treatment nationwide, commits...

September 26, 2025

Coordinated transcranial magnetic stimulation, ketamine may benefit refractory depression

Coordinating transcranial magnetic stimulation (TMS) with ketamine therapy shows promising potential...